{"title":"美国糖尿病协会-第70届科学会议-新疗法的研究:第2部分。","authors":"Gary Croasdell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"598-600"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.\",\"authors\":\"Gary Croasdell\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 9\",\"pages\":\"598-600\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.
The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
